Management of Steroid-Refractory Immune-Related Adverse Events

Oncology (Williston Park). 2019 Aug 23;33(8):683727.
No abstract available

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • Colitis / chemically induced
  • Colitis / drug therapy
  • Colitis / immunology
  • Colitis / pathology
  • Disease Management
  • Drug Resistance, Neoplasm
  • Hepatitis / drug therapy
  • Hepatitis / etiology
  • Hepatitis / immunology
  • Hepatitis / pathology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Pneumonia / chemically induced
  • Pneumonia / drug therapy
  • Pneumonia / immunology
  • Pneumonia / pathology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Steroids / pharmacology*

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • Immunosuppressive Agents
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Steroids